NCT02435472 (ASX) is a NA clinical trial of Exercise in Localized Prostate Cancer, sponsored by University of California, San Francisco.

Who is sponsoring NCT02435472?

NCT02435472 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT02435472?

Interventions in NCT02435472: Exercise, Cardiopulmonary Exercise Test (CPET).

What condition does NCT02435472 study?

NCT02435472 studies Localized Prostate Cancer, Active Surveillance for Prostate Cancer.

Is NCT02435472 still recruiting?

NCT02435472 is currently completed. Last updated 11 April 2025.

Last reviewed 2025-04-11 · How we verify

NCT02435472: ASX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Active Surveillance Exercise Clinical Trial

Completed NA Last updated 11 April 2025

What this trial tests

NA trial testing Exercise in Localized Prostate Cancer in 104 participants. Completed in 31 December 2024.

Timeline

21 June 2016

Primary endpoint
30 April 2023

31 December 2024

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	104
Start date	21 June 2016
Primary completion	30 April 2023
Estimated completion	31 December 2024
Sites	1 location across United States

Drugs / interventions tested

Exercise
Cardiopulmonary Exercise Test (CPET)

Conditions studied

Localized Prostate Cancer — all drugs for Localized Prostate Cancer →
Active Surveillance for Prostate Cancer — all drugs for Active Surveillance for Prostate Cancer →

Sponsor

University of California, San Francisco

Who can join

18 and older, male only, with Localized Prostate Cancer or Active Surveillance for Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase 2, open-label, dual-center, two-arm randomized controlled trial (RCT) investigates the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance). Prostate genomic signatures represent the functional activity of all genes in the genome and are converted into genomic risk scores which correspond to the probability of a progression event (chance of having more aggressive disease). A structured exercise program may alter the genomic risk score and improve prediction of aggressive disease.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Diet and lifestyle considerations for patients with prostate cancer.
Zuniga KB, Chan JM, Ryan CJ, Kenfield SA. · · 2020 · cited 36× · PMID 31327752 · DOI 10.1016/j.urolonc.2019.06.018
Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer.
Kenfield SA, Van Blarigan EL, Panchal N, Bang A, et al · · 2021 · cited 20× · PMID 34636156 · DOI 10.1002/cam4.4324

Verify or expand the search:

Other trials of Exercise

Trials testing the same drug.

NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
NCT07589725 — Mulligan Mobilization in Lateral Elbow Tendinopathy · NA · not yet recruiting
NCT07524400 — Effects of Physical Exercise Combined With Transcranial Direct Current Stimulation in Parkinson's Disease · NA · recruiting
NCT06627569 — Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans · NA · not yet recruiting

Other recruiting trials for Localized Prostate Cancer

Currently open trials in the same condition.

NCT06966778 — Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial · NA · recruiting
NCT06825091 — Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE) · Phase 3 · recruiting
NCT06117059 — The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance · NA · recruiting
NCT06325774 — Radical Hypofractionated Radiotherapy for Localized Prostate Cancer · NA · recruiting
NCT06362577 — Clinical Study of HIFU for Localized Prostate Cancer · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02435472 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 11 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02435472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing